Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Vaccitech

Vaccitech
2016 FOUNDED
PRIVATE STATUS
Grant LATEST DEAL TYPE
$8.5M LATEST DEAL AMOUNT
11 INVESTORS
Description

Developer of therapeutic vaccine technology created for the treatment of seasonal flu and prostate cancer. The company's therapeutic vaccine technology includes live-attenuated, killed whole-cell and subunit antigen vaccines that deliver either one or two heterologous viral vector vaccines, each encoding the same antigen, several weeks to months apart, enabling patients to improve the protection provided by the seasonal flu vaccination.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • The Schrodinger Building Heatley Road
  • The Oxford Science Park
  • Oxford OX4 4GE
  • England, United Kingdom

+44 01865 000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Vaccitech’s full profile, request a free trial.

Vaccitech Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 07-Mar-2019 $8.5M 0000 Completed Clinical Trials - Phase 2
3. Early Stage VC 20-Dec-2018 00.000 0000 000.00 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 14-Jan-2018 $27M $41.4M Completed Clinical Trials - Phase 2
1. Seed Round 10-May-2016 $14.4M $14.4M 000.00 Completed Product Development
To view this company’s complete deal history including valuation and funding, request access »

Vaccitech Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 0,000 00.000000 00000.00 00000.00 00 00000.00 0.000
Series A 00,000 00.000000 00000.00 00000.00 00 00000.00 00.000
Ordinary 13,333 $0.012718 $953.81 $953.81 1x $953.81 31.86%
Ordinary 133 $0.012718 $956.2 $956.2 1x $956.2 0.32%
To view this company’s complete Cap Table, request access »

Vaccitech Competitors (35)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Turnstone Biologics Venture Capital-Backed Ottawa, Canada 00 00000 000000000000 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
000000000 Formerly VC-backed Culver City, CA 000 00000 00000000000 00000
00000000 Venture Capital-Backed Uppsala, Sweden 00 0000000000
000 0000000000000 Formerly VC-backed Princeton, NJ 00 00.000 000000 - 000 00.000
To view this company’s complete list of competitors, request access »

Vaccitech Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Biomedical Advanced Research and Development Authority Corporation 000 0000 000000 0
Genematrix Corporation Minority 000 0000 000000 0
Korea Investment Partners Venture Capital Minority 000 0000 000000 0
GV Corporate Venture Capital Minority 000 0000 000000 0
Neptune Restaurant Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Vaccitech Executive Team (6)

Name Title Board
Seat
Contact
Info
Thomas Evans MD Chief Executive Officer & Board Member
Chris Ellis Chief Operating Officer
Keith Howard Ph.D Chief Development Officer
Sarah Gilbert Co-Founder & Professor of Vaccinology
Graham Griffiths Chief Business Officer
You’re viewing 5 of 6 executives. Get the full list »

Vaccitech Board Members (7)

Name Representing Role Since Contact
Info
Adrian Hill Vaccitech Co-Founder & Board Member 000 0000
Andrew McLean MD Oxford Sciences Innovation Board Member 000 0000
Pierre Morgon Self Board Member 000 0000
Robin Wright Self Chairman 000 0000
Steven Chatfield Ph.D Self Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 7 board members. Get the full list »